Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Wockhardt: Strong performance - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Apr 29, 2002

    Wockhardt: Strong performance

    Wockhardt Ltd. has declared encouraging results for 1QFY03. While sales have grown by more than 27%, net profit forged ahead by 37%. The impressive performance in sales is on the back of strong growth in export formulations and key brands in the domestic market. The peformance of the company is above our expectations of 20% growth.

    (Rs m) 1QFY02 1QFY03 Change
    Net sales 1,303 1,653 26.9%
    Other Income - 1 -
    Expenditure 1,056 1,341 27.0%
    Operating Profit (EBDIT) 247 312 26.3%
    Operating Profit Margin (%) 19.0% 18.9%  
    Interest 37 20 -
    Depreciation 27 33 22.2%
    Profit before Tax 183 260 42.1%
    Other Adjustments - -  
    Tax 10 23 130.0%
    Profit after Tax/(Loss) 173 237 37.0%
    Net profit margin (%) 13.3% 14.3%  
    No. of Shares (eoy) (m) 36.3 36.3  
    Diluted Earnings per share 19.1 26.1  
    P/E (at current price)   21.6  

    On a consolidated basis, with the company's UK subsidiary -- Wallis Lab -- sales for the quarter registered a growth of 21% to Rs 1.9 bn. The growth was driven by focus on key strategic products in the domestic market, which have recorded more than 50% growth during the period. Overall. domestic sales posted a growth of 22%, against the industry average of 11%. Exports jumped 46% mainly on the back of 110% rise in formulations export. Formulations now constitute 35% of total exports on a trailing 12-month basis. During the quarter, the company also firmed up a multi-product development, supply, sales and marketing alliance with Ranbaxy Laboratories Ltd.

    During the quarter, the company took over entire equity holding in Wockhardt Rhein Biopharm Ltd. (WRBL) WRBL was a joint venture company between Wockhardt Ltd. (WL) and Rhein Biotech GmbH, Germany, each holding 50% of the capital. WRBL is now a wholly owned subsidiary of Wockhardt.

    The biotech products of the company continue to log attractive growth rates. Wockhardt is expecting one product introduction every year from its biotech division. Besides these, the product lineup of the company seems to be strong with various combinational vaccines, typhoid vaccine and other drugs in lifestyle therapeutics (chronic segment). The company is consciously shifting its revenue mix towards chronic segment where growth and margins are higher compared to acute segment.

    Read more on Wockhardt

    At the current market price of Rs 565, the stock is currently trading at 18x our FY03 expected earnings.



    Equitymaster requests your view! Post a comment on "Wockhardt: Strong performance". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

    Aug 21, 2017

    Most Indians who cannot find jobs, look at becoming self-employed.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

    Aug 22, 2017

    Post demonetisation, a cut in bank savings deposits rates was in the offing.

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 24, 2017 10:58 AM


    • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks



    Compare Company With Charts